RTI Biologics launches new biologic implant for orthopedic and spine surgeries (Equities)
RTI Biologics Inc., or RTI, a processor of orthopedic, dental, surgical specialties and other biologic implants, has launched a new biologic implant for use in sports medicine, orthopedic and spine surgeries.
According to the company, BioReady DBM Putty is an extension of RTI Biologics’ DBM portfolio which includes BioSet DBM Paste and BioAdapt Foam. It is a demineralized bone matrix (DBM) implant that provides convenience, robust handling, verified osteoinductive potential and sterility.
BioReady DBM Putty and Putty with Chips are 100% allograft, and each donor lot is tested for osteoinductive potential. This implant does not require any preparation, such as thawing or mixing, and it is available in various sizes for use as a bone void filler in many types of surgical procedures, the company added.
RTI’s implants are sterilized through processes validated by tissue type. BioReady DBM Putty is sterilized through the Cancelle SP Demineralization Process. Through a combination of oxidative treatments and acid or alcohol washes, cellular debris is removed and pathogens are inactivated.
“BioReady is an exciting allograft solution that complements our portfolio of DBM implants including BioSet and BioAdapt,” said Roger Rose, executive vice president and chief commercial officer for RTI Biologics. “This ready-to-use implant addresses a significant clinical need and ensures that we maximize every gift of donation received.”